Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Skip to content

The immunological effects of continuous veno-venous haemodiafiltration in critically ill patients

Metadata Updated: September 7, 2025

Background: Haemodynamic instability is common in septic patients with acute renal failure. Continuous veno-venous haemodiafiltration (CVVHD) is therefore used as an alternative to conventional haemodialysis. Haemodialysis is associated with an activation of the immune system. The aim of the present study was to test the hypothesis that initiation of CVVHD influences the immune system with release of proinflammatory cytokines followed by a decrease in granulocyte activation, as assessed by the expression of adhesion molecules.

      Results:
      Fifteen patients were included. Mean Acute Physiology and Chronic
            Health Evaluation-2 score before CVVHD was 19 (range 8⌓27). Mean duration of
            CVVHD treatment was 9 days (1⌓21 days). Tumour necrosis factor-α and
            interleukin-8 were detectable in plasma in all patients, whereas interleukin-10
            was detectable only in a few patients. Proinflammatory and anti-inflammatory
            cytokines were detected in the ultrafiltrate. Large intraindividual and
            interindividual variations were demonstrated for all of the immunological
            parameters studied.


      Conclusion:
      The hypothesis that CVVHD induces the release of proinflammatory
            cytokines followed by a decrease in granulocyte activation was not confirmed in
            the present study. The heterogeneous group of patients studied, with different
            underlying diseases and various durations of illness before the start of CVVHD,
            might have contributed to the difficulty in demonstrating the proposed
            immunological effect of CVVHD.

Access & Use Information

Public: This dataset is intended for public access and use. License: No license information was provided. If this work was prepared by an officer or employee of the United States government as part of that person's official duties it is considered a U.S. Government Work.

Downloads & Resources

Dates

Metadata Created Date July 24, 2025
Metadata Updated Date September 7, 2025

Metadata Source

Harvested from Healthdata.gov

Additional Metadata

Resource Type Dataset
Metadata Created Date July 24, 2025
Metadata Updated Date September 7, 2025
Publisher National Institutes of Health
Maintainer
NIH
Identifier https://healthdata.gov/api/views/ynri-u4sm
Data First Published 2025-07-13
Data Last Modified 2025-09-06
Category NIH
Public Access Level public
Bureau Code 009:25
Metadata Context https://project-open-data.cio.gov/v1.1/schema/catalog.jsonld
Metadata Catalog ID https://healthdata.gov/data.json
Schema Version https://project-open-data.cio.gov/v1.1/schema
Catalog Describedby https://project-open-data.cio.gov/v1.1/schema/catalog.json
Harvest Object Id 72676f98-3b74-45e9-8b69-e12a6ea2c04b
Harvest Source Id 651e43b2-321c-4e4c-b86a-835cfc342cb0
Harvest Source Title Healthdata.gov
Homepage URL https://healthdata.gov/d/ynri-u4sm
Program Code 009:033
Source Datajson Identifier True
Source Hash 7cbebf938e848603b3fcf040d760736490a6d43fb098363160c9bdfb8416cec4
Source Schema Version 1.1

Didn't find what you're looking for? Suggest a dataset here.